User:Mac/Agenda: Difference between revisions
< User:Mac
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
== 18 Jan 2010 == | |||
* <strike>write 1 paragraph / section of paper outline</strike> | |||
== 11 Jan 2010 == | |||
* <strike>Got [http://www.genome.duke.edu/people/faculty/angrist/ Misha's] Feedback</strike> | |||
** read this: [http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cntvwrPtlt{actionForm.contentReference}=committees%2Ftechnology%2Fivdmia.html&_state=maximized&_pageLabel=cntvwr College of American Pathologists POET report on IVDMIAs] | |||
* Get Annual Reports from key companies listed; summarize | |||
* Add papers about [[Diagnostic_Kits/Commons_based_cases_in_Kits#GDx_Reference_Materials | GDx reference materials from Journal of Molecular Diagnostics]] | |||
Check out this market report w/r/t multivariate testing: http://www.insightpharmareports.com/Reports_report.aspx?id=71450&r=555 | |||
== 2 Dec 2009 TODO == | == 2 Dec 2009 TODO == | ||
[[Mac/Agenda/2-Dec-2009|work completed]] | [[Mac/Agenda/2-Dec-2009|work completed]] | ||
| Line 15: | Line 31: | ||
* read last chapter's of Gene Cartels | * read last chapter's of Gene Cartels | ||
* <strike> read SACGHS Report final draft </strike> | * <strike> [[SACGHS_Appendix_1-_Compendium_of_Case_Studies_on_the_Impact_of_Gene_Patents_and_Licensing_Practices_on_Access_to_Genetic_Testing| read SACGHS Report final draft]] </strike> | ||
* back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.") | * back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.") | ||
** http://cyber.law.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/The_Argument_Framework&direction=next&oldid=4910 | ** http://cyber.law.harvard.edu/commonsbasedresearch/?title=Diagnostic_Kits/The_Argument_Framework&direction=next&oldid=4910 | ||
Revision as of 16:57, 19 January 2010
18 Jan 2010
write 1 paragraph / section of paper outline
11 Jan 2010
Got Misha's Feedback
- Get Annual Reports from key companies listed; summarize
- Add papers about GDx reference materials from Journal of Molecular Diagnostics
Check out this market report w/r/t multivariate testing: http://www.insightpharmareports.com/Reports_report.aspx?id=71450&r=555
2 Dec 2009 TODO
- add GDx / PGx from SACGHS appendix and PGx paper to the case studies (~15?)
- Add OTC genetic tests to the list
- move to no.2, overall picture of kits
- write 1 paragraph / section of paper outline
- centralize answers to "do patents harm researchers?"
complete field definition- 1st draftcomplete data, narratives, tools defn, build off of Ford report sectionget basic market stats / picture (just GDx)- partial; just national ref labs
- read last chapter's of Gene Cartels
read SACGHS Report final draft- back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.")
Duke team, Luigi interview
- come up w/ questions
- position on IVDMIAs
- use interview framework from EM
Identify people to ask about IVDMIA tests
- look at federal docket of comments in response to draft guideline
- ask the 5 OTC companies in interview